FoxO1 suppresses Fgf21 during hepatic insulin resistance to impair peripheral glucose utilization and acute cold tolerance

por Stöhr, Oliver, Tao, Rongya, Miao, Ji, Copps, Kyle D., White, Morris F.
Publicado 2021

Hepatic follistatin increases basal metabolic rate and attenuates diet-induced obesity during hepatic insulin resistance

por Tao, Rongya, Stöhr, Oliver, Wang, Caixia, Qiu, Wei, Copps, Kyle D., White, Morris F.
Publicado 2023

Insulin signaling and reduced glucocorticoid receptor activity attenuate postprandial gene expression in liver

por Kalvisa, Adrija, Siersbæk, Majken S., Præstholm, Stine M., Christensen, Line J. L., Nielsen, Ronni, Stohr, Oliver, Vettorazzi, Sabine, Tuckermann, Jan, White, Morris, Mandrup, Susanne, Grøntved, Lars
Publicado 2018

Inactivating hepatic follistatin alleviates hyperglycemia

por Tao, Rongya, Wang, Caixia, Stöhr, Oliver, Qiu, Wei, Hu, Yue, Miao, Ji, Dong, X. Charlie, Leng, Sining, Stefater, Margaret, Stylopoulos, Nicholas, Lin, Lin, Copps, Kyle D., White, Morris F.
Publicado 2018

TAZ inhibits glucocorticoid receptor and coordinates hepatic glucose homeostasis in normal physiological states

por Xu, Simiao, Liu, Yangyang, Hu, Ruixiang, Wang, Min, Stöhr, Oliver, Xiong, Yibo, Chen, Liang, Kang, Hong, Zheng, Lingyun, Cai, Songjie, He, Li, Wang, Cunchuan, Copps, Kyle D, White, Morris F, Miao, Ji
Publicado 2021